Moderna, Inc. (MRNA) announced on Tuesday that its next-generation COVID-19 vaccine design mRNA-1283 has met the primary endpoints of the NextCOVE Phase 3 clinical trial.
The trial showed a positive immune response against SARS-CoV-2 compared to Moderna's licensed COVID-19 vaccine, mRNA-1273.222.
The NEXTCove study involved around 11,400 participants aged 12 years and older in the United States, United Kingdom, and Canada.
The most common side effects reported were injection site pain, headache, fatigue, myalgia, and chills.
Moderna stated that it will share a detailed analysis of the Phase 3 trial data for mRNA-1283 at its Vaccines Day event on March 27 and in upcoming scientific conferences.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.